Glucagon-like peptide-1 (GLP-1) receptor agonists, such as exenatide, liraglutide, and semaglutide, can enhance myocardial sensitivity to insulin, improve the glucose uptake rate, promote myocardial energy metabolism, and inhibit cardiomyocyte apoptosis, which contributes to the treatment of DCM [78–80]. This evidence concerns the gene INS and familial dilated cardiomyopathy.